Wuhan Hiteck Biological Pharma Co (SZSE:300683) ROCE % : -4.13% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Wuhan Hiteck Biological Pharma Co's annualized ROCE % for the quarter that ended in Mar. 2024 was -4.13%.

Wuhan Hiteck Biological Pharma Co ROCE % Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co ROCE % Chart

Wuhan Hiteck Biological Pharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

4.13

-2.05

0.98

-0.28

-5.93

Wuhan Hiteck Biological Pharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-1.01	-2.55	-3.55	-15.43	-4.13

Wuhan Hiteck Biological Pharma Co ROCE % Calculation

Wuhan Hiteck Biological Pharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-149.596	/	( ( (2706.855 - 284.734)	+	(2971.251 - 346.146) )	/ 2 )
	=	-149.596	/	( (2422.121	+	2625.105)	/ 2 )
	=	-149.596	/	2523.613
	=	-5.93 %

Wuhan Hiteck Biological Pharma Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-109.028	/	( ( (2971.251 - 346.146)	+	(2965.34 - 311.034) )	/ 2 )
	=	-109.028	/	( ( 2625.105	+	2654.306 )	/ 2 )
	=	-109.028	/	2639.7055
	=	-4.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Wuhan Hiteck Biological Pharma Co (SZSE:300683) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Wuhan Hiteck Biological Pharma Co ROCE % Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056

Website

http://www.hiteck.com.cn

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.

Executives

Yan Jie	Director
Li Sheng Qiang	Executives

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Headlines

No Headlines